Passage Bio ( (PASG) ) has issued an update.
Passage Bio, a genetic medicines company, reported significant progress in their PBFT02 gene therapy trials for FTD-GRN, revealing promising interim data that shows potential as a leading progranulin-raising therapy. With patient enrollment on track and robust preclinical data presented at key scientific conferences, the company is poised to achieve critical milestones, supported by a strong financial position ensuring operations until mid-2026. This progress underscores Passage Bio’s commitment to advancing treatments for neurodegenerative diseases.
For an in-depth examination of PASG stock, go to TipRanks’ Stock Analysis page.
